The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa1500925

PMID

27050206

PICO

Population

Patients with grade 2 astrocytoma, oligoastrocytoma, or oligodendroglioma, age <40 with subtotal resection/biopsy or age ≥40 with any resection/biopsy

Intervention

Radiation therapy followed by six cycles of procarbazine, CCNU, and vincristine (PCV) chemotherapy

Comparator

Radiation therapy alone

Outcomes

Overall survival, progression-free survival

Design

Type

Phase III randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

Not applicable: open-label trial

Follow-up

Median 11.9 years

Primary endpoint

Overall survival

Secondary endpoints

Progression-free survival
Histologic prognostic variables

Practice impact

What this means

This phase III RCT demonstrates that adding PCV chemotherapy to radiation therapy significantly improves both progression-free and overall survival in adults with grade 2 gliomas. With median follow-up of 11.9 years, the radiation+PCV group had 5.5 years longer median overall survival (13.3 vs 7.8 years) and double the 10-year progression-free survival (51% vs 21%). This supports adjuvant PCV for eligible patients despite its toxicity profile.

Bottom line

Addition of PCV chemotherapy to radiation improves both progression-free and overall survival in eligible grade 2 glioma patients

Strength of evidence

high

Recommendation

change practice

Why it matters

Randomized phase III trial with long-term follow-up
Statistically significant improvement in overall survival (HR 0.59, P=0.003)
Absolute 20% improvement in 10-year overall survival

What would change my mind

Superior results with temozolomide-based regimens in similar populations
Subgroup analysis showing benefit limited to specific molecular subtypes
Long-term toxicity data outweighing survival benefit

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low: randomized, stratified by age, histology, KPS, and contrast enhancement

Confounding

Minimal: randomization and stratification balanced known prognostic factors

Missing data

Not reported in excerpt; likely minimal given long follow-up and 55% mortality

Multiplicity

Not addressed for secondary endpoints; primary endpoint analysis appropriate

Notes

Open-label design may introduce bias in progression assessment
Long follow-up strengthens survival data

Stats check

NNT

Not provided

Effect sizes

HR 0.59 for death (95% CI not provided in excerpt, P=0.003)

Absolute effects

Median overall survival 13.3 years vs 7.8 years
10-year overall survival 60% vs 40%
10-year progression-free survival 51% vs 21%

Concerns

Confidence intervals for HR not in excerpt
No adjustment for multiple comparisons on secondary endpoints

External validity

Who it applies to

Adult patients with grade 2 gliomas meeting inclusion criteria, particularly those with oligodendroglioma histology

Who it does not

Patients with grade 1 or 3-4 gliomas, pediatric populations, those unable to tolerate PCV chemotherapy

Generalizability notes

Histology based on WHO 2007 classification; modern molecular classification may affect applicability
PCV regimen used rather than temozolomide

Evidence trace

Source trace and metadata

Citations (4)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Methods

quote

Patients were randomly assigned to radiation therapy alone or to radiation therapy followed by six cycles of combination chemotherapy.

claim_id

stats_check.effect_sizes

locator

p. 1 Results

quote

hazard ratio for death, 0.59; P=0.003

claim_id

stats_check.absolute_effects

locator

p. 1 Results

quote

median overall survival (13.3 vs. 7.8 years)

claim_id

practice_impact.bottom_line

locator

p. 1 Results

quote

progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years